Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
about
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cellsLoss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesisThe 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugsPIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancersMolecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsPim1 kinase synergizes with c-MYC to induce advanced prostate carcinomaUpstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expressionGrowth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cellsNotch signaling in prostate cancer: refining a therapeutic opportunitySingle and Multiple Gene Manipulations in Mouse Models of Human CancerObesity and cancer: mechanistic insights from transdisciplinary studiesAndrogen receptor and prostate cancer stem cells: biological mechanisms and clinical implicationsTranslating insights of AR signaling from mouse modelsGenetically engineered mouse models of prostate cancerMYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsAssociation of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell CarcinomaMeta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymesRole of the TMPRSS2-ERG gene fusion in prostate cancerIntegrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and oldInhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerThe Bysl gene product, bystin, is essential for survival of mouse embryosDisruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formationId4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTENConcurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionMYC on the path to cancerAdditive Effect of Zfhx3/Atbf1 and Pten Deletion on Mouse Prostatic TumorigenesisTherapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimeticProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.Bioinformatics approaches for cross-species liver cancer analysis based on microarray gene expression profiling.Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibilityMultiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumorsCombined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesisAndrogen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulationBRAF activation initiates but does not maintain invasive prostate adenocarcinomaAccumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer modelA core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum responseMYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
P2860
Q24302137-D2CB3279-FB9B-4C32-AA56-3E423D781E66Q24314483-388FDC5B-2A81-4252-8204-D63EFDEA1649Q24336934-EBF44905-483A-4BAD-8259-AD6207DE87D1Q24603099-CF298E99-67AB-46BE-AFFD-2702A8AC1AAFQ24629083-05B8F19F-2DFD-41FF-A659-1EFE82B8609EQ24630639-15D9648E-3E40-4FAE-AC92-90F241FB9656Q24655749-24FA5A2F-A09A-43B5-8E89-A4F58889A4EEQ25257791-DEA98164-EBDA-4E35-A82E-E0863456F809Q26777624-0220EEA5-C7BD-46CC-AC44-42F294CD5679Q26783920-57AB354E-B637-4CF8-B103-E95DF3560E12Q26786829-B959922A-01CE-4ED7-8483-4B727347C6D2Q26797063-BB53C3B8-47A3-4D33-AE8F-E6C10BCCFB90Q27014822-BAE9381E-0BD7-4279-9F37-649D49CE5D68Q27026768-BC59D8C2-2883-486D-836C-0847BA41C549Q27350187-F1E13681-087E-45E7-B8EE-6ECEA84A64E8Q27853352-FAC07FDD-992D-4418-9F1C-7C21EE1BD13CQ28085759-662E83E2-6462-4800-9C93-D36C5FB90B48Q28269156-8C211087-19CD-426D-8182-6CFBD4B4041FQ28396741-AD6EE216-BC9C-4350-ACBF-31EB48D41A4CQ28541342-0E41B666-1520-424D-B332-FF6BB8C359CDQ28586642-B771F58C-7BAC-481F-A73C-79038A4F7B85Q28588760-740E87A9-779F-44E6-BA6D-D8EE4CB849F7Q28592943-E83F104E-9684-494A-8C7F-38921CD7819CQ28743074-21D49E51-98A9-4207-85D8-0A6731A1F623Q29619979-D1EA5C38-A26C-42A9-94B0-0185C27C2768Q30278925-BF69E351-3A8C-48BC-BD4C-C982E6C2BD40Q30300019-762EE95E-CDA7-47BE-86BC-0BC4F54BD033Q30409623-44EF936B-7BB5-4A1C-9376-B349C04F0E99Q30410016-6C77696B-9835-45E3-B41D-67F1726878AAQ30444311-2FFD0355-855A-4D38-9C0F-94A58DFEDABEQ30866782-411F4422-6C4F-4AEA-8AA0-31075EBF9A6BQ33219782-54DBF405-698E-4427-ABB7-4FAC24638112Q33314433-FF31B339-5E71-4B4E-97D4-4D4DF7335256Q33324395-1CB01807-B29B-4FCC-8763-ACFE209A8BD4Q33340980-AFB2CA5B-A7E7-42A3-916C-F72706ED34C5Q33390573-E74DB6A1-C8A3-48D7-9864-FA16CE7317F7Q33392719-276381E4-E240-4AF9-9CF0-F1ABF34C4E22Q33450599-500A707C-9A4F-477C-8E32-3E5DAA90E642Q33494820-BD69B975-1B3B-45F1-9A63-942007D7EB01Q33535955-72266ABD-BEAD-4806-AC5C-1BC039B2E055
P2860
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
@en
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
@nl
type
label
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
@en
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
@nl
prefLabel
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
@en
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
@nl
P2093
P1433
P1476
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
@en
P2093
Charles L Sawyers
George V Thomas
JianFeng Zhang
John Wongvipat
Katharine Ellwood-Yen
M Luisa Iruela-Arispe
Robert Matusik
P304
P356
10.1016/S1535-6108(03)00197-1
P577
2003-09-01T00:00:00Z